Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec;6(1):6.
doi: 10.1186/s40169-017-0135-8. Epub 2017 Jan 18.

Tissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why?

Paul Zarogoulidis  1 , Mina Gaga  2 , Haidong Huang  3 , Kaid Darwiche  4 , Aggeliki Rapti  5 , Wolfgang Hohenforst-Schmidt  6
Affiliations

Tissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why?

Paul Zarogoulidis et al. Clin Transl Med. 2017 Dec.

Abstract

Lung cancer is still the leading cause of death among all cancers. During the last 15 years, pharmacogenomics of lung cancer have established targeted therapy with tyrosine kinase inhibitors (TKIs) for epidermal growth factor receptor (EGFR) positive patients in adenocarcinoma or mixed adenosquamus lung cancer patients. However; while novel drugs are released in the market, at the same time novel mutations are observed after tyrosine kinase inhibitor administration. Recently the novel mutation T790 was observed and is highly prevalent in patients already treated with a TKI. A new drug targeting this mutation is already on the market, however; the most important factor for successful treatment in these patients, is adequate tissue re-sampling so that novel mutations can be detected.

Keywords: Biopsy; Ebus; Egfr; Lung cancer; t790.

PubMed Disclaimer

References

    1. Soejima K, Yasuda H, Hirano T. Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer. Expert Rev Clin Pharmacol. 2016 - PubMed
    1. Yap TA, Macklin-Doherty A, Popat S. Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. Eur J Cancer. 2016;70:12–21. doi: 10.1016/j.ejca.2016.10.014. - DOI - PubMed
    1. Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, et al. Treatment of non-small cell lung cancer (NSCLC) J Thorac Dis. 2013;5(Suppl 4):S389–S396. - PMC - PubMed
    1. Agrawal S, Feng Y, Roy A, Kollia G, Lestini B. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer. 2016;4:72. doi: 10.1186/s40425-016-0177-2. - DOI - PMC - PubMed
    1. Hopkins E, Moffat D, Parkinson I, Robinson P, Jersmann H, Dougherty B, et al. Cell block samples from endobronchial ultrasound transbronchial needle aspiration provide sufficient material for ancillary testing in lung cancer-a quaternary referral centre experience. J Thorac Dis. 2016;8:2544–2550. doi: 10.21037/jtd.2016.08.74. - DOI - PMC - PubMed